Johnson & Johnson's HIV Drug Rilpivirine Passes Phase III Trials but Stumbles on Virologic Failure
SCRIP -- Johnson & Johnson's non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (TMC278) was safe and effective in two Phase III trials of treatment-naïve HIV-patients, showed data presented last week at the 18th International AIDS conference in Austria. Both the ECHO and THRIVE studies...